TSHA Stock Forecast & Price Target

Taysha Gene Therapies is viewed positively because TSHA-102 is showing unusually strong early efficacy in Rett syndrome, with an 83% six-month response rate that rose to 100% at 12 months in 12 patients, far above the FDA’s 33% benchmark. The breadth of benefit is also compelling, as the program has delivered 31 developmental milestones, 310 total functional gains, and improvements in communication, sleep, seizures, and motor skills, suggesting meaningful clinical impact across age groups. Fundamentally, the outlook is further strengthened by a favorable safety profile across 29 treated patients with no treatment-related SAEs or DLTs, while the fully enrolled pivotal study and 1H27 readout provide a clear near-term catalyst.

Taysha Gene Therapies is challenged by the high failure rate of clinical development, as TSHA-102 may never prove sufficiently safe or effective in current or future trials, especially given prior adverse events seen in AAV-based gene therapy such as severe immunological responses and DRG toxicity. Regulatory risk is substantial because none of its drugs have been approved by the FDA or EMA, intrathecal gene therapies face added scrutiny, and delays or denials would hurt commercialization prospects. The competitive and financial backdrop is also weak: Acadia’s Daybue was approved in March 2023, Neurogene has a Phase I Rett program, and Taysha may need additional equity financing, creating dilution risk as it funds costly development and a future sales force.